Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: Results from a pooled analysis

Journal of Hematology and Oncology

Volumn 8, Issue 1, 2015, Pages

  Di Lauro, Luigi ^a   Pizzuti, Laura ^a   Barba, Maddalena ^a   Sergi, Domenico ^a   Sperduti, Isabella ^a   Mottolese, Marcella ^a   Amoreo, Carla Azzurra ^a   Belli, Franca ^b   Vici, Patrizia ^a   Speirs, Valerie ^c   Santini, Daniele ^d   De Maria, Ruggero ^a   Maugeri Saccà, Marcello ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b Italian Charcot Marie Tooth Association (AICMT) Clinic   (Italy)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Aromatase inhibitors; Cyproterone acetate; Gonadotropin releasing hormone analogue; Male breast cancer; Metastatic disease

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; CYPROTERONE ACETATE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GONADORELIN DERIVATIVE; METHOTREXATE; TAMOXIFEN; GONADORELIN;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE BREAST CANCER; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS, MALE; FEMALE; METABOLISM; METASTASIS; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AROMATASE INHIBITORS; BREAST NEOPLASMS, MALE; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; YOUNG ADULT;

EID: 84930678440     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-015-0147-z     Document Type: Article

References (25)

1. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer. 2004;101:51-7.
2. White J, Kearins O, Dodwell D, Horgan K, Hanby AM, Speirs V. Male breast carcinoma: increased awareness needed. Breast Cancer Res. 2011;13:219.
3. Shaaban AM, Ball GR, Brannan RA, Cserni G, Di Benedetto A, Dent J, et al. A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Res Treat. 2012;133:949-58.
4. Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol. 2010;28:232-9.
5. Eggemann H, Ignatov A, Smith BJ, Altmann U, von Minckwitz G, Röhl FW, et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat. 2013;137:465-70.
6. Doyen J, Italiano A, Largillier R, Ferrero JM, Fontana X, Thyss A. Aromatase inhibition in male breast cancer patients: biological and clinical implications. Ann Oncol. 2010;21:1243-5.
7. Zagouri F, Sergentanis TN, Koutoulidis V, Sparber C, Steger GG, Dubsky P, et al. Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. Br J Cancer. 2013;108:2259-63.
8. Di Lauro L, Vici P, Del Medico P, Laudadio L, Tomao S, Giannarelli D, et al. Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. Breast Cancer Res Treat. 2013;141:119-23.
9. Zagouri F, Sergentanis TN, Chrysikos D, Zografos E, Rudas M, Steger G, et al. Fulvestrant and male breast cancer: a case series. Ann Oncol. 2013;24:265-6.
10. Zagouri F, Sergentanis TN, Chrysikos D, Dimopoulos MA, Psaltopoulou T. Fulvestrant and male breast cancer: a pooled analysis. Breast Cancer Res Treat. 2015;149:269-75.
11. Lopez M. Cyproterone acetate in the treatment of metastatic cancer of the male breast. Cancer. 1985;55:2334-6.
12. Lopez M, Natali M, Di Lauro L, Vici P, Pignatti F, Carpano S. Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer. Cancer. 1993;72:502-5.
13. Di Lauro L, Vici P, Barba M, Pizzuti L, Sergi D, Rinaldi M, et al. Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series. Breast Cancer Res Treat. 2014;148:73-80.
14. Callari M, Cappelletti V, De Cecco L, Musella V, Miodini P, Veneroni S, et al. Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Res Treat. 2011;127:601-10.
15. Giordano SH, Hortobagyi GN. Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol. 2006;24:e42-3.
16. Mauras N, O'Brien KO, Klein KO, Hayes V. Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab. 2000;85:2370-7.
17. T'Sjoen GG, Giagulli VA, Delva H, Crabbe P, De Bacquer D, Kaufman JM. Comparative assessment in young and elderly men of the gonadotropin response to aromatase inhibition. J Clin Endocrinol Metab. 2005;90:5717-22.
18. Bighin C, Lunardi G, Del Mastro L, Marroni P, Taveggia P, Levaggi A, et al. Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated with aromatase inhibitors. Oncologist. 2010;15:1270-2.
19. Leder BZ, Rohrer JL, Rubin SD, Gallo J, Longcope C. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endocrinol Metab. 2004;89:1174-80.
20. Burnett-Bowie SA, Roupenian KC, Dere ME, Lee H, Leder BZ. Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf). 2009;70:116-23.
21. Maugeri-Saccà M, Barba M, Vici P, Pizzuti L, Sergi D, De Maria R, et al. Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations. Breast Cancer Res Treat. 2014;147:227-35.
22. Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010;28:2114-22.
23. Labrie F, Bélanger A, Luu-The V, Labrie C, Simard J, Cusan L, et al. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev. 2005;26:361-79.
24. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer. Cancer. 1977;39:1289-94.
25. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-14.